These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38045053)

  • 1. Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infection.
    Zhao X; Feng J; Zhang J; Han Z; Hu Y; Shao HH; Li T; Xia J; Lei K; Wang W; Lai F; Lin Y; Liu B; Zhang K; Zhang C; Yang Q; Luo X; Zhang H; Li C; Zhang W; Wu S
    Acta Pharm Sin B; 2023 Dec; 13(12):4945-4962. PubMed ID: 38045053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
    Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
    Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
    Grossman TH; Bartels DJ; Mullin S; Gross CH; Parsons JD; Liao Y; Grillot AL; Stamos D; Olson ER; Charifson PS; Mani N
    Antimicrob Agents Chemother; 2007 Feb; 51(2):657-66. PubMed ID: 17116675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.
    Durcik M; Lovison D; Skok Ž; Durante Cruz C; Tammela P; Tomašič T; Benedetto Tiz D; Draskovits G; Nyerges Á; Pál C; Ilaš J; Peterlin Mašič L; Kikelj D; Zidar N
    Eur J Med Chem; 2018 Jun; 154():117-132. PubMed ID: 29778894
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Barman TK; Kumar M; Mathur T; Namba E; Singh D; Chaira T; Kurosaka Y; Yamada M; Upadhyay DJ; Masuda N
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
    Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
    PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents.
    Durcik M; Tomašič T; Zidar N; Zega A; Kikelj D; Mašič LP; Ilaš J
    Expert Opin Ther Pat; 2019 Mar; 29(3):171-180. PubMed ID: 30686070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
    Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
    Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
    Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
    Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
    D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
    PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
    Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
    Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents.
    Eakin AE; Green O; Hales N; Walkup GK; Bist S; Singh A; Mullen G; Bryant J; Embrey K; Gao N; Breeze A; Timms D; Andrews B; Uria-Nickelsen M; Demeritt J; Loch JT; Hull K; Blodgett A; Illingworth RN; Prince B; Boriack-Sjodin PA; Hauck S; MacPherson LJ; Ni H; Sherer B
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1240-6. PubMed ID: 22183167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode.
    Lu J; Patel S; Sharma N; Soisson SM; Kishii R; Takei M; Fukuda Y; Lumb KJ; Singh SB
    ACS Chem Biol; 2014 Sep; 9(9):2023-31. PubMed ID: 24992706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.
    Durcik M; Tammela P; Barančoková M; Tomašič T; Ilaš J; Kikelj D; Zidar N
    ChemMedChem; 2018 Jan; 13(2):186-198. PubMed ID: 29206345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
    East SP; White CB; Barker O; Barker S; Bennett J; Brown D; Boyd EA; Brennan C; Chowdhury C; Collins I; Convers-Reignier E; Dymock BW; Fletcher R; Haydon DJ; Gardiner M; Hatcher S; Ingram P; Lancett P; Mortenson P; Papadopoulos K; Smee C; Thomaides-Brears HB; Tye H; Workman J; Czaplewski LG
    Bioorg Med Chem Lett; 2009 Feb; 19(3):894-9. PubMed ID: 19095445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an
    Huang J; Guo S; Li X; Yuan F; Li Y; Xu B; Gu J; Qiao Y
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0180021. PubMed ID: 34902266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
    Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
    Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.